{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:25:36Z","timestamp":1780590336731,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T00:00:00Z","timestamp":1683763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007515","name":"Universidad de Valladolid","doi-asserted-by":"publisher","award":["GRS\/2180\/A\/2020"],"award-info":[{"award-number":["GRS\/2180\/A\/2020"]}],"id":[{"id":"10.13039\/501100007515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007515","name":"Universidad de Valladolid","doi-asserted-by":"publisher","award":["GRS\/2351\/A\/2021"],"award-info":[{"award-number":["GRS\/2351\/A\/2021"]}],"id":[{"id":"10.13039\/501100007515","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.prp.2023.154514","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T17:20:00Z","timestamp":1683825600000},"page":"154514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Multigene germline testing usefulness instead of BRCA1\/2 single screening in triple negative breast cancer cases"],"prefix":"10.1016","volume":"247","author":[{"given":"M.","family":"Arranz-Ledo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lastra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Abella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Orozco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dur\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.prp.2023.154514_bib1","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","article-title":"An overview of triple-negative breast cancer","volume":"293","author":"Kumar","year":"2016","journal-title":"Arch. Gynecol. Obstet."},{"issue":"2","key":"10.1016\/j.prp.2023.154514_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-016-4059-6","article-title":"Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer","volume":"161","author":"Li","year":"2017","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.prp.2023.154514_bib3","series-title":"Critical Reviews in Oncology\/Hematology","article-title":"Triple negative breast cancer: a thorough review of biomarkers","author":"da Silva","year":"2020"},{"issue":"8","key":"10.1016\/j.prp.2023.154514_bib4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djy106","article-title":"Triple-negative breast cancer risk genes identified by multigene hereditary cancer panel testing","volume":"110","author":"Shimelis","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"55","key":"10.1016\/j.prp.2023.154514_bib5","first-page":"552","article-title":"NCCN guidelines updates: breast cancer","volume":"17","author":"Telli","year":"2019","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"2","key":"10.1016\/j.prp.2023.154514_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s12094-019-02262-0","article-title":"SEOM clinical guidelines in hereditary breast and ovarian cancer (2019)","volume":"22","author":"Gonz\u00e1lez-Santiago","year":"2020","journal-title":"Clin. Transl. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2023.154514_bib7","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.2014.57.1414","article-title":"Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer","volume":"33","author":"Couch","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2023.154514_bib8","first-page":"1","article-title":"A comprehensive custom panel evaluation for routine hereditary cancer testing: Improving the yield of germline mutation detection","volume":"18","author":"Vel\u00e1zquez","year":"2020","journal-title":"J. Transl. Med [Internet]"},{"issue":"13","key":"10.1016\/j.prp.2023.154514_bib9","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2015.65.0747","article-title":"Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer","volume":"34","author":"Tung","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.prp.2023.154514_bib10","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.jgo.2020.11.008","article-title":"Breast cancer associated pathogenic variants among women 61\u00a0years and older with triple negative breast cancer","volume":"12","author":"Ch\u00e1varri-Guerra","year":"2021","journal-title":"J. Geriatr. Oncol."},{"issue":"11","key":"10.1016\/j.prp.2023.154514_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12113140","article-title":"Ngs panel testing of triple-negative breast cancer patients in Cyprus: A study of BRCA-negative cases","volume":"12","author":"Zanti","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2023.154514_bib12","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4821-8","article-title":"Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria","volume":"18","author":"Hoyer","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2023.154514_bib13","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CCO.0000000000000784","article-title":"Genetic testing in patients with triple-negative or hereditary breast cancer","volume":"Vol. 33","author":"Bernstein-Molho","year":"2021","journal-title":"Curr. Opin. Oncol. NLM"},{"issue":"2","key":"10.1016\/j.prp.2023.154514_bib14","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.siny.2017.11.010","article-title":"Genetic counselling, patient education, and informed decision-making in the genomic era","volume":"23","author":"Metcalfe","year":"2018","journal-title":"Semin Fetal Neonatal Med [Internet]"},{"issue":"1","key":"10.1016\/j.prp.2023.154514_bib15","first-page":"6","article-title":"Incidental findings from cancer next generation sequencing panels","author":"Maani","year":"2021","journal-title":"npj Genom. Med [Internet]"},{"issue":"1","key":"10.1016\/j.prp.2023.154514_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-020-01554-6","article-title":"Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers","volume":"39","author":"Federici","year":"2020","journal-title":"J. Exp. Clin. Cancer Res"},{"key":"10.1016\/j.prp.2023.154514_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2022.06.003","article-title":"Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D","author":"Graffeo","year":"2022","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.prp.2023.154514_bib18","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.amjsurg.2018.08.008","article-title":"Factors predicting reclassification of variants of unknown significance","volume":"216","author":"Wright","year":"2018","journal-title":"Am. J. Surg."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823002145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033823002145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:58:00Z","timestamp":1759733880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033823002145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":18,"alternative-id":["S0344033823002145"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2023.154514","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multigene germline testing usefulness instead of BRCA1\/2 single screening in triple negative breast cancer cases","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2023.154514","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"154514"}}